Peer Review History

Original SubmissionSeptember 21, 2022
Decision Letter - Michael Klymkowsky, Editor

PONE-D-22-26088Human embryonic stem cells secrete macrophage migration inhibitory factor: A novel findingPLOS ONE

Dear Dr. zhao,

Forgive us for the time that has pasted you submitted your manuscript - it has been difficult to get reviews, so I have decided to proceed with one review.  After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please directly address the points raised by this reviewer, send include a copy of your responses and changes/additions to the manuscript. 

Please submit your revised manuscript by Jun 01 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Michael Klymkowsky, Ph.D.

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. Please provide abstract in English.

3. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

4. Thank you for stating the following financial disclosure:

“Funding: This work was supported by a grant from National Natural Science Foundation of China (grant numbers 81860238); Hainan Provincial Natural Science Foundation of China (grant number 821RC694); Major Research and Development Project of Hainan Province of China (grant number ZDYF2018233); Scientific research projects in Colleges and Universities of Hainan Province of China; Project of Hainan Province Clinical Medical Center;

Author Contributions

Zhenqiang Zhao and Jingquan Li conceived and designed the work, took part in all the works. Yanzhao Wei and Xiaohan Zheng were responsible for experiments,statistical analysis and writing of the manuscript.Ting Huang,Shengtong Sun,Xufang Wei and Qibing Liu were responsible for data collection and statistical analysis.”

Please state what role the funders took in the study.  If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.""

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

5. Thank you for stating the following in the Acknowledgments Section of your manuscript:

“This work was supported by a grant from National Natural Science Foundation of China (grant numbers 81860238); Hainan Provincial Natural Science Foundation of China (grant number 821RC694); Major Research and Development Project of Hainan Province of China (grant number ZDYF2018233); Scientific research projects in Colleges and Universities of Hainan Province of China; Project of Hainan Province Clinical Medical Center;”

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“Funding: This work was supported by a grant from National Natural Science Foundation of China (grant numbers 81860238); Hainan Provincial Natural Science Foundation of China (grant number 821RC694); Major Research and Development Project of Hainan Province of China (grant number ZDYF2018233); Scientific research projects in Colleges and Universities of Hainan Province of China; Project of Hainan Province Clinical Medical Center;

Author Contributions

Zhenqiang Zhao and Jingquan Li conceived and designed the work, took part in all the works. Yanzhao Wei and Xiaohan Zheng were responsible for experiments,statistical analysis and writing of the manuscript.Ting Huang,Shengtong Sun,Xufang Wei and Qibing Liu were responsible for data collection and statistical analysis.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

6. Thank you for stating the following in your Competing Interests section: 

“NO authors have competing interests”

Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state ""The authors have declared that no competing interests exist."", as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now

This information should be included in your cover letter; we will change the online submission form on your behalf.

7. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

8. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

9. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ.

10. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is an interesting and original paper that shows that MIF is also produced grom human embrionic stem cells.

The Authors also demonstrate that MIF acts in HESC via binding to CXCR2 and CXCR7 and not through convebtional receptors such as CD74 and CD44.

While the finding is original and of interest its biological meaning remains elusive.

I have several points of concerns on the paper as it stands:

1. have the Authors evaluated whether HESC also secrete MIF-2 (DDT) ? There is no mention to MIF2 (DDT) in the paper and this point is of particular interest (PMID 30439447; PMID 30682543). In anycase the existence and possible secretion of DDT from HESC needs to be discussed

2. For search of completeness the Authors should discuss that MIF is implicated in several autoimmune diseases (PMID 18721909)

3. The statement that MIF suppresses tumour formation needs to be restated as the action of MIF in oncogenesis is complex and often dicothomic and may also favour tumor formation and progression (PMID 32769903; PMID 32155795; PMID 31867451; PMID 3334425)

4. As several specific MIF inhibitors are being developed and a semispecific inhibitor, ibidulast is already in the clinical setting, the present finding of the Authors of MIf production from HESC and the discussed potentil role of MIF in embryogenesis makes it important to mention that MIF inhibition during pregnancy should be carefullly evaluated

5. the paper is too long and could be reduced by 20%

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Response to Academic Editors

1.This revision has been revised according to the PLOS ONE style template.

2.English abstracts have been provided.

3.The funding information has been changed in Edit Manager and the grant number has been verified.

4.Author contribution modified to “Zhenqiang Zhao and Tan Wang conceived and designed the work, took part in all the works. Yanzhao Wei and Xiaohan Zheng were responsible for experiments, statistical analysis and writing of the manuscript. Ting Huang, Yuanji Zhong, Shengtong Sun, Xufang Wei and Qibing Liu were responsible for data collection and statistical analysis. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.” Modified text is marked in blue.

5.The grant-related text in the manuscript has been removed. Our funding statement is amended as follows:

This work was supported by a grant from National Natural Science Foundation of China (grant number 81860238); Hainan Provincial Natural Science Foundation of China (grant number 821RC694); Major Research and Development Project of Hainan Province of China (grant number ZDYF2018233); Scientific research projects in Colleges and Universities of Hainan Province of China (grant number HYYS2021A19); Project of Hainan Province Clinical Medical Center. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Modified text is marked in blue.

6.“The authors have declared that no competing interests exist.” has stated in the cover letter. Modified text is marked in blue.

7.Data availability is modified to “All relevant data are within the paper and its Supporting information files.” Modified text is marked in blue.

8.blot/gel image data has been added to the supporting information

9.ORCID iD of the corresponding author has been added in the Editorial Manager.

10.The title of the supporting information has been added at the end of the manuscript.

Responses to reviewers

1.This revision adds a discussion of DDT to the discussion section. Modified text is marked in blue.

2.This revision adds the relationship of MIF to autoimmune diseases to the discussion section. Modified text is marked in blue.

3.The role of MIF in tumorigenesis has been removed due to the deletion of the text mentioned in point 5.

4.Due to the role of MIF in embryonic stem cells, MIF suppression during pregnancy should be evaluated as well. Modified text is marked in blue.

5.The text of this paper has been appropriately abridged to make it more concise.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Michael Klymkowsky, Editor

Human embryonic stem cells secrete macrophage migration inhibitory factor: A novel finding

PONE-D-22-26088R1

Dear Dr. zhao,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Michael Klymkowsky, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

Formally Accepted
Acceptance Letter - Michael Klymkowsky, Editor

PONE-D-22-26088R1

Human embryonic stem cells secrete macrophage migration inhibitory factor: A novel finding

Dear Dr. Zhao:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Michael Klymkowsky

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .